Bibliography
- Hoffmann M, Kumar G, Schafer P, et al. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. Xenobiotica 2011;41(12):1063–75
- Otezla (apremilast) [prescribing information]. Celgene Corporation; Summit, NJ: 2014
- Wu A, Rohane P, Ng J, et al. Safety/tolerability and pharmacokinetics of multiple oral doses of apremilast in healthy male subjects [abstract]. Clin Pharmacol Ther 2012;91:S26
- Cada DJ, Ingram K, Baker DE. Apremilast. Hosp Pharm 2014;49(8):752–62
- Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012;83(12):1583–90
- Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates antiinflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010;159(4):842–55
- Straub RH, Bijlsma JW, Masi A, et al. Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases--the 10-year update. Semin Arthritis Rheum 2013;43(3):392–404
- Cutolo M, Mease PJ, Gladman DD, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in tender and swollen joint counts in patients with psoriatic arthritis: results from three Phase III, randomized, controlled trials. Arthritis Rheum 2013;65:S135–6
- Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Longterm (52-week) results of a Phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol 2015. [Epub ahead of print]
- Cutolo M, Myerson GE, Fleischmann RM, et al. Long-Term (52-Week) results of a Phase III, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2) [abstract]. Arthritis Rheum 2013;65(Suppl 10):815
- Edwards CJ, Blanco FJ, Crowley J, et al. Long-term 52-week results of PALACE 3, a Phase III, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement [abstract 212]. Rheumatology 2014;53(Suppl 1):i138
- Schett G, Mease PJ, Gladman DD, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in physical function in patients with psoriatic arthritis: results from three Phase III, randomized, controlled trials. Arthritis Rheum 2013;65:S143
- Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a Phase III, randomized, controlled trial. Arthritis Rheum 2012;64(12):4172–3
- Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: results from 3 Phase III, randomized, controlled trials [abstract 548]. Arthritis Rheum 2014;66(11 Suppl):S239
- Apremilast, an oral phosphodiesterase 4 inhibitor, and the impact of baseline weight and BMI on ACR20 and HAQ-DI response: pooled results from 3 Phase III, randomized, controlled trials [abstract 1561]. Arthritis Rheum 2014;66(11 Suppl):S689
- Mease PJ, Kavanaugh A, Gladman D, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three Phase III, randomized, controlled trials [abstract SAT0408]. Ann Rheum Dis 2014;73(Suppl2):742
- Mease PJ. Apremilast: phosphodiesterase 4 inhibitor for the treatment of psoriatic arthritis. Rheumatol Ther 2014;1:1–20
- Mease PJ, Kavanaugh A, Adebajo A, et al. Laboratory abnormalities in patients with psoriatic arthritis receiving apremilast, an oral phosphodiesterase 4 inhibitor: pooled safety analysis of three Phase III, randomized, controlled trials [abstract 348]. Arthritis Rheum 2013;65(10 Suppl):S151
- Long-term (104-week) safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a Phase III, randomized, controlled trial and open-label extension (PALACE 1) [abstract 1564]. Arthritis Rheum 2014;66(11 Suppl):S690
- Tashkin DP. Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin Pharmacother 2014;15(1):85–96
- Change in weight from baseline with apremilast, an oral phosphodiesterase 4 inhibitor: pooled results from 3 Phase III, randomized, controlled trials [abstract 1579]. Arthritis Rheum 2014;66(11 Suppl):S698
- Wouters EF, Teichmann P, Brose M, et al. Effects of roflumilast, a phosphodiesterase 4 inhibitor, on body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:A4473